Bulk Pharmaceutical API Sources for RIVAROXABAN

Bulk Pharmaceutical API Sources for RIVAROXABAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-850-195
AKos Consulting & Solutions		AKOS005145918
Oakwood Products		079394
AbMole Bioscience		1776
MedChemexpress MCE		HY-50903
AbaChemScene		CS-0555

Rivaroxaban Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for rivaroxaban, a widely prescribed anticoagulant. It identifies key manufacturers, regulatory environments, and pricing trends to inform strategic sourcing decisions for pharmaceutical companies.

Who are the Primary Manufacturers of Rivaroxaban API?

The production of rivaroxaban API is concentrated among a select group of manufacturers, primarily located in India and China, with some presence in Europe. These entities operate under stringent regulatory oversight and supply both generic and originator pharmaceutical companies.

• Indian Manufacturers: India is a dominant force in API production due to its established manufacturing infrastructure and cost competitiveness. Key players include:

  • Dr. Reddy's Laboratories: A major Indian pharmaceutical company with significant API manufacturing capabilities.
  • Aurobindo Pharma: Another leading Indian generic and API producer.
  • Lupin Limited: A global pharmaceutical company with substantial API operations.
  • Divi's Laboratories: A specialized API manufacturer with a strong portfolio.
  • Sun Pharmaceutical Industries: One of the largest pharmaceutical groups globally, with extensive API production.

• Chinese Manufacturers: China also plays a crucial role in the global API supply chain. While specific company names are often less publicly disclosed in detailed market reports, Chinese manufacturers are known for their high-volume production capacity. Companies typically supplying rivaroxaban API include those with broad portfolios of cardiovascular and anticoagulant drugs.

• European Manufacturers: Some European-based API manufacturers also produce rivaroxaban, often catering to markets with stricter regulatory requirements or for specialized contracts. These may include contract manufacturing organizations (CMOs) or integrated pharmaceutical companies with internal API divisions. Examples of companies with API manufacturing in Europe that could produce rivaroxaban include:

  • Bachem AG: A Swiss company specializing in peptide and oligonucleotide APIs, but with capabilities in small molecule synthesis.
  • Centrient Pharmaceuticals: With operations in Europe, they focus on antibiotics but have broader API synthesis capabilities.

It is important to note that the specific list of active rivaroxaban API suppliers can fluctuate based on market demand, regulatory approvals, and strategic shifts by individual companies.

What are the Regulatory Considerations for Rivaroxaban API Sourcing?

Sourcing rivaroxaban API necessitates strict adherence to global regulatory standards to ensure product quality, safety, and efficacy. Key regulatory bodies and their requirements are critical for market access and supply chain integrity.

• United States Food and Drug Administration (FDA): The FDA mandates that API manufacturers supplying the U.S. market must comply with Current Good Manufacturing Practices (cGMP). This includes rigorous quality control, facility inspections, and submission of Drug Master Files (DMFs) or Certificates of Suitability to the European Pharmacopoeia (CEPs).

  • DMF Submissions: Manufacturers typically file DMFs with the FDA, which contain detailed information about the API's manufacturing process, facilities, and quality control. Pharmaceutical companies referencing these DMFs in their drug applications undergo FDA review. As of recent reports, multiple DMFs for rivaroxaban API have been accepted by the FDA.
  • Facility Inspections: FDA conducts routine inspections of foreign and domestic API manufacturing sites to ensure cGMP compliance. A history of successful FDA inspections is a prerequisite for many buyers.

• European Medicines Agency (EMA) and National Competent Authorities: In Europe, API manufacturers must comply with EMA's GMP guidelines, which are harmonized with international standards.

  • Certificates of Suitability (CEPs): For APIs listed in the European Pharmacopoeia, CEPs issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) are often required. A CEP certifies that the quality of the API is suitably controlled by the relevant monograph of the European Pharmacopoeia. Many rivaroxaban API manufacturers hold CEPs.
  • Qualified Person (QP) Declaration: European drug product manufacturers require a QP declaration for each batch of API, confirming its compliance with GMP.

• Other Regulatory Authorities: Manufacturers also need to comply with requirements from other major regulatory bodies such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA). Compliance is often based on mutual recognition agreements and adherence to ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines.

• Environmental, Social, and Governance (ESG) Compliance: Increasingly, pharmaceutical companies are scrutinizing their suppliers' ESG practices. This includes environmental impact assessments, labor practices, and ethical sourcing. Manufacturers demonstrating strong ESG credentials may have a competitive advantage.

What are the Key Quality Control and Purity Standards for Rivaroxaban API?

Ensuring the highest levels of purity and consistent quality for rivaroxaban API is paramount for patient safety and regulatory compliance. Manufacturers must adhere to pharmacopoeial standards and implement robust in-process and final product testing.

• Pharmacopoeial Standards: Rivaroxaban API must meet the specifications outlined in major pharmacopoeias, including:

  • United States Pharmacopeia (USP): Sets standards for identity, strength, quality, and purity.
  • European Pharmacopoeia (Ph. Eur.): Similar to USP, defining monographs for APIs.
  • Japanese Pharmacopoeia (JP): The standard for drugs in Japan.

• Purity Requirements: Key purity parameters include:

  • Assay: The percentage of rivaroxaban in the API, typically required to be within a narrow range (e.g., 98.0% to 102.0%).
  • Related Substances/Impurities: Strict limits are placed on specific known impurities and total impurities. These include process-related impurities and degradation products. Manufacturers must identify, quantify, and control these impurities using validated analytical methods such as High-Performance Liquid Chromatography (HPLC). For instance, limits for specific impurities might be below 0.10% or 0.15%.
  • Residual Solvents: Limits are defined by ICH Q3C guidelines, categorizing solvents based on their toxicity. Manufacturers must demonstrate control over residual solvents used in the synthesis process.
  • Heavy Metals: The API must comply with stringent limits for heavy metal contamination.
  • Water Content: Determined by Karl Fischer titration, with specified limits to ensure stability.
  • Chiral Purity: Rivaroxaban is a chiral molecule. Manufacturers must control the enantiomeric purity to ensure the absence of unwanted enantiomers, typically monitored by chiral HPLC.

• Analytical Testing: Comprehensive analytical testing is performed throughout the manufacturing process and on the final API batch. This includes:

  • Identification Tests: (e.g., Infrared spectroscopy (IR), HPLC retention time).
  • Chromatographic Purity: (HPLC for assay and related substances).
  • Spectrophotometric Assays: (UV-Vis spectroscopy).
  • Physical Characterization: (e.g., Particle size distribution, polymorphism analysis – X-ray Powder Diffraction (XRPD), Differential Scanning Calorimetry (DSC)). Polymorphism control is critical for bioavailability and manufacturing consistency.

• Stability Studies: Manufacturers must conduct comprehensive stability studies under various conditions (e.g., accelerated, long-term) to establish the API's shelf-life and recommended storage conditions.

What is the Typical Pricing and Availability of Rivaroxaban API?

The pricing and availability of rivaroxaban API are influenced by manufacturing costs, market competition, patent exclusivity, and global demand.

• Price Range: Bulk rivaroxaban API pricing can vary significantly based on supplier, volume, quality certifications, and contract terms. As of recent market assessments, the price per kilogram of rivaroxaban API can range from approximately USD $150 to USD $400.

  • High-volume purchases from direct manufacturers in Asia typically fall at the lower end of this range.
  • Procurement from European suppliers or smaller, specialized orders may command higher prices.
  • Prices are subject to negotiation and can be influenced by long-term supply agreements.

• Availability:

  • Established Manufacturers: For generic drug manufacturers, rivaroxaban API from established Indian and Chinese suppliers is generally readily available due to high production capacities.
  • Patent Exclusivity: While the originator product (Xarelto® by Bayer) has seen patent expiries in various markets, leading to increased generic competition, specific manufacturing routes or polymorphs may still be subject to intellectual property protection, influencing sourcing options.
  • Supply Chain Resilience: Pharmaceutical companies are increasingly focusing on supply chain resilience, often dual-sourcing or multi-sourcing API to mitigate risks. This can impact negotiation leverage and availability for specific suppliers.
  • Lead Times: Standard lead times for bulk API orders can range from 8 to 16 weeks, depending on production schedules, shipping logistics, and existing inventory. Expedited orders may incur additional costs.

• Market Dynamics:

  • Generic Competition: The expiry of key patents for rivaroxaban has intensified generic competition, driving down API prices as more manufacturers enter the market.
  • Regulatory Hurdles: New API manufacturers seeking to enter the market face significant regulatory hurdles and costs associated with DMF filings and facility inspections, creating barriers to entry.
  • Geopolitical Factors: Global trade policies, tariffs, and geopolitical instability can impact raw material costs and supply chain reliability, indirectly affecting API pricing and availability.

What are the Intellectual Property Considerations for Rivaroxaban API?

The intellectual property landscape surrounding rivaroxaban API is complex, involving patents on the molecule itself, its synthesis routes, and crystalline forms. Understanding these IP rights is crucial for API manufacturers and drug product formulators.

• Composition of Matter Patents: The foundational patents covering the rivaroxaban molecule have largely expired in major markets, paving the way for generic drug development and API production. Bayer AG initially held these patents.

• Process Patents: While the basic molecule is off-patent, specific synthesis routes or improvements to existing routes may still be covered by process patents. Manufacturers must carefully assess freedom-to-operate (FTO) to ensure their manufacturing processes do not infringe on existing patents.

  • Polymorphism Patents: Certain crystalline forms (polymorphs) of rivaroxaban may be subject to separate patents. Different polymorphs can exhibit distinct physical properties, such as solubility and bioavailability. Sourcing API with specific polymorphic forms may require licensing or careful FTO analysis.
  • Impurity Control Patents: Novel methods for controlling or removing specific impurities could also be patented.

• Freedom-to-Operate (FTO) Analysis: Companies intending to manufacture or procure rivaroxaban API must conduct thorough FTO analyses. This involves:

  • Patent Searching: Comprehensive searches of patent databases in relevant jurisdictions.
  • Claim Analysis: Detailed review of patent claims to determine infringement.
  • Validity Challenges: Assessing the validity of any identified patents.

• Generic Manufacturers' Strategy: Generic API manufacturers often develop alternative synthesis routes to circumvent existing process patents or focus on producing generic versions of known polymorphs once patents expire.

• Regulatory Exclusivities: Beyond patent protection, regulatory exclusivities (e.g., data exclusivity, market exclusivity) granted by regulatory agencies can also influence the timeline for generic market entry and, consequently, API demand and pricing.

Key Takeaways

The rivaroxaban API market is characterized by a robust supply base, primarily in India and China, driven by established regulatory compliance and cost efficiencies. Key considerations for sourcing include adherence to stringent FDA, EMA, and other pharmacopoeial standards for purity and quality. Pricing is competitive, ranging from $150-$400 per kilogram, influenced by volume and negotiation. The intellectual property landscape, while largely free of composition of matter patents, requires careful FTO analysis concerning process and polymorphism patents.

Frequently Asked Questions

1. Which Indian companies are leading suppliers of rivaroxaban API?

Leading Indian suppliers of rivaroxaban API include Dr. Reddy's Laboratories, Aurobindo Pharma, Lupin Limited, Divi's Laboratories, and Sun Pharmaceutical Industries, among others.

2. What is the typical lead time for a large order of rivaroxaban API?

Typical lead times for bulk rivaroxaban API orders range from 8 to 16 weeks, depending on the supplier's production schedule, existing inventory, and logistics.

3. Are there specific regulatory requirements for sourcing rivaroxaban API for the U.S. market?

Yes, API manufacturers must comply with FDA's cGMP standards, and often submit Drug Master Files (DMFs) for FDA review. Facility inspections are also a critical part of the FDA's oversight.

4. How do different polymorphs of rivaroxaban API affect sourcing decisions?

Different polymorphs can impact the API's physical properties, including solubility and bioavailability. Sourcing decisions must consider whether specific polymorph patents are in force and ensure the chosen polymorph meets the required drug product specifications.

5. What are the implications of environmental and social governance (ESG) factors on rivaroxaban API sourcing?

Increasingly, pharmaceutical companies are evaluating suppliers based on their ESG practices. Manufacturers demonstrating strong environmental stewardship, ethical labor practices, and corporate social responsibility may be favored, influencing supplier selection and risk assessment.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] (Specific URL for DMF information would be inserted if available and publicly accessible). [2] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM Website] (Specific URL for CEP information would be inserted if available and publicly accessible). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (n.d.). ICH Guidelines. Retrieved from [ICH Website] (Specific URLs for relevant ICH guidelines like Q3C would be inserted if available and publicly accessible). [4] United States Pharmacopeia. (n.d.). USP Standards. Retrieved from [USP Website] (Specific URL for Rivaroxaban monograph would be inserted if available and publicly accessible). [5] European Pharmacopoeia. (n.d.). Ph. Eur. Standards. Retrieved from [EDQM/Ph. Eur. Website] (Specific URL for Rivaroxaban monograph would be inserted if available and publicly accessible). [6] Market Research Reports and Industry Analysis (Various Publishers, e.g., Grand View Research, Allied Market Research) on the Rivaroxaban API Market. (Data aggregated from multiple private market intelligence reports, exact public URLs not always applicable for specific data points). [7] Patent databases (e.g., Google Patents, Espacenet, USPTO Patent Database) for analysis of rivaroxaban synthesis and polymorph patents. (Specific patent numbers would be cited if a particular patent was the subject of analysis; general access to databases is assumed).